Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00189904 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

A Phase 1 study of HIV Infections, sponsored by Bavarian Nordic.

Completed
Registry status
Phase 1
Development phase
151
Enrollment target
5
Study locations

NCT00189904: Completed Phase 1 study of HIV Infections, sponsored by Bavarian Nordic.

NCT00189904 is a Phase 1 study of HIV Infections that has completed, run by Bavarian Nordic. The registered enrollment target is 151 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00189904, a Phase 1 study of HIV Infections, has completed, sponsored by Bavarian Nordic.

COMPLETED
Registry status
Phase 1
Development phase
151 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.

Conditions Studied

Interventions

  • BIOLOGICAL IMVAMUNE (MVA-BN)

Study Locations (5)

Indiana

  • Indiana University School of Medicine - Indianapolis

Kentucky

  • University of Kentucky Medical Center - Lexington

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • University of Pennsylvania - Philadelphia

Tennessee

  • Vanderbilt AIDS Clinical Trials Center - Nashville

Trial Details

FieldValue
Enrollment Target 151 participants
Start Date 2005-07
Phase Phase 1
Bavarian Nordic

41 total trials

What the finished NCT00189904 record still lists

NCT00189904 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (66% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which IMVAMUNE (MVA-BN) is the first listed.

NCT00189904 lists 5 locations in 5 states (Indiana, Kentucky, Missouri).

Frequently Asked Questions

What is clinical trial NCT00189904 about?

NCT00189904 is a clinical study titled "Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients". The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.

What is the current status of trial NCT00189904?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2005-07.

What conditions does trial NCT00189904 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00189904?

The interventions under investigation include: IMVAMUNE (MVA-BN) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00189904?

This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00189904 being conducted?

This trial has 5 study locations across Indiana, Kentucky, Missouri, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00189904's enrollment target sits among peer trials

151 211th of 542 higher than 332 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01409161 · 151 participants · Phase 2

    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

  • NCT04245397 · 151 participants · Phase 1

    Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

  • NCT05761223 · 151 participants · Phase 1

    A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

  • NCT07195656 · 151 participants · NA

    Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00189904, the US trial registry maintained by the National Library of Medicine. NCT00189904 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.